Stay updated on ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.

Latest updates to the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.4.2; removed the long funding-status notice and Revision: v3.4.1. The update does not affect the study details or how the page is used.SummaryDifference0.3%

- Check21 days agoChange DetectedAdded a site-wide notice about government funding status and NIH CC operations. Updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.3%

- Check28 days agoChange DetectedMinor UI and metadata updates were made, including a glossary toggle, updated QC labeling, capitalization adjustments for the No FEAR Act notice, and an updated site revision from v3.3.4 to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedThe revision label on the page updated from v3.3.3 to v3.3.4, reflecting a small metadata update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check64 days agoChange DetectedAdded a consolidated Locations section listing study sites by state (California, Colorado, Florida, Indiana, Iowa, Massachusetts, Michigan, Minnesota, Tennessee, Texas, Utah, Virginia). Removed the individual per-state location sections and updated the page to Revision: v3.3.3.SummaryDifference1%

- Check85 days agoChange DetectedRevision: v3.3.2 was added and v3.3.1 was removed; no changes to the study details page are visible.SummaryDifference0.0%

Stay in the know with updates to ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.